Intellia reports phase 3 HAELO trial success for lonvo-z
Intellia released positive Phase 3 data for its HAE treatment lonvo-z, received FDA guidance, and ended the quarter with strong liquidity.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day